AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05113446 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Delirium assessment using S-CAM
Description: Twice a day, the rounds of nurses in shifts, 8:00 am - 10:00 am, 4:00 pm - 6:00 pm Trained research assistants assessed delirium using S-CAM
Study NCT06090110 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagal Nerve Stimulation
Description: Transcutaneous Auricular Vagal Nerve Stimulation
Study NCT06090110 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation with a non-conduction electrode
Study NCT04817826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).
Study NCT04817826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: tremelimumab 300 mg single administration (day 1)
Study NCT06166680 — intervention group
Intervention type: OTHER
Intervention: Sleep quality assessment
Description: The following item will be assessed in all subjects (n=420):~1. Sleep, through the Pediatric Sleep Questionnaire.
Study NCT06166680 — intervention group
Intervention type: OTHER
Intervention: Anthropometry
Description: The following items will be assessed in all subjects (n=420):~2. Anthropometric data : 2.1 Height; 2.2 Weight; 2.3 Maximal mouth opening; 2.4 Maximal mouth opening with tongue to palate (with the Quick Tongue-Tie assessment tool)
Study NCT06166680 — intervention group
Intervention type: OTHER
Intervention: Tongue strength assessment
Description: The following items will be assessed in all subjects (n=420):~3. Tongue pressure (in kPa) exerted against the IOPI (Iowa Oral Performance Instrument) bulb while swallowing.~4. Tongue peak pressure (i.e., the maximal pressure - Pmax - exerted against the IOPI bulb) during 3 sec. of tongue elevation.~5. Tongue peak pressure during 3 sec. of tongue protrusion.
Study NCT06166680 — intervention group
Intervention type: OTHER
Intervention: Tongue endurance assessment
Description: The following items will be assessed in all subjects (n=420):~6. The tongue endurance (i.e., the time to task failure in maintaining a pressure equal to 50%Pmax against the IOPI bulb) during tongue elevation.~7. The tongue endurance during tongue protrusion.
Study NCT06166680 — intervention group
Intervention type: OTHER
Intervention: Orofacial praxis assessment
Description: - The following item will be assessed in a subset of subjects (n=31): 8. Orofacial praxis through the Motricité Bucco-Linguo-Faciale (MBLF) test.
Study NCT05322200 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: A computerized tomography (CT) coronary angiogram
Description: Participants in both arms will undergo CT coronary angiogram with Plaque Map analysis at baseline prior to therapy initiation and following 12 months of treatment.
Study NCT05322200 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: A computerized tomography (CT) coronary angiogram
Description: Participants in both arms will undergo CT coronary angiogram with Plaque Map analysis at baseline prior to therapy initiation and following 12 months of treatment.
Study NCT05322200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vicorder (Skidmore medical, UK)
Description: Participants in both arms will undergo aortic carotid-femoral pulse wave velocity (cfPWV)through the Vicorder (Skidmore medical, UK), which uses oscillometric cuff-based measurements to establish the index of arterial stiffness. The procedure will be done at baseline and 12 months after therapy initiation.
Study NCT05322200 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Vicorder (Skidmore medical, UK)
Description: Participants in both arms will undergo aortic carotid-femoral pulse wave velocity (cfPWV)through the Vicorder (Skidmore medical, UK), which uses oscillometric cuff-based measurements to establish the index of arterial stiffness. The procedure will be done at baseline and 12 months after therapy initiation.
Study NCT05322200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood tests for inflammation and oxidative stress markers
Description: All the participants will have (non-fasting) blood samples performed to assess serum glucose, lipid profile and serum biomarkers for plaque initiation (Lipid profile, LpPLA2), endothelial activation (MCP-1), plaque inflammation (hsCRP, IL6, IL18, TNF, advanced glycation end-products), vulnerable transformation (vEGF, PAI-1, BMP-6) and measures of oxidative stress (Ox-LDL, TAOS, TBARs) at baseline, and at 12 months after therapy initiation
Study NCT05322200 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood tests for inflammation and oxidative stress markers
Description: All the participants will have (non-fasting) blood samples performed to assess serum glucose, lipid profile and serum biomarkers for plaque initiation (Lipid profile, LpPLA2), endothelial activation (MCP-1), plaque inflammation (hsCRP, IL6, IL18, TNF, advanced glycation end-products), vulnerable transformation (vEGF, PAI-1, BMP-6) and measures of oxidative stress (Ox-LDL, TAOS, TBARs) at baseline, and at 12 months after therapy initiation
Study NCT05292248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Confidently Navigating Financial Decisions and Enhancing Financial Wellbeing in Dementia Caregiving
Description: Multicomponent psychoeducational intervention focused on financial wellbeing
Study NCT05065359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rodatristat Ethyl 300 mg BID
Description: Tablets, oral, 300 mg, BID 14 days
Study NCT05804123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl physiological saline Nasal-spraying
Description: 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
Study NCT05065359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rodatristat Ethyl 600 mg BID
Description: Tablets, oral, 600 mg, BID 14 days
Study NCT05804123 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LiveSpo Navax®
Description: In Vietnam, LiveSpo Navax® is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016
Study NCT05804123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Augmentin 500Mg Tablet
Description: Augmentin (GlaxoSmithKline Pte, product declaration No. VN-20169-16) is an oral antibiotic available in the form of 625 mg tablets, which are prescribed as routine treatment for children and adults, respectively.
Study NCT05065359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, oral, 0 mg, BID for 14 days
Study NCT06504810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: light
Description: light level
Study NCT06482931 — intervention group
Intervention type: OTHER
Intervention: Quality of life questionnaires
Description: Patients will be asked to fill in two quality of life questionnaires: PACT-Q and EQ-5D-5L.
Study NCT06375057 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic cholecystectomy
Description: A blood sample is taken the day after surgery
Study NCT06504810 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: light
Description: light level
Study NCT05804123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Augmentin 500Mg Tablet
Description: Augmentin (GlaxoSmithKline Pte, product declaration No. VN-20169-16) is an oral antibiotic available in the form of 625 mg tablets, which are prescribed as routine treatment for children and adults, respectively.
Study NCT05804123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylcysteine
Description: Acetylcysteine 200 mg (STADA Vietnam, product declaration No. VD-22667-15) is an oral expectorant, which is prescribed as routine treatment for children and adults, respectively.
Study NCT05804123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: Acetylcysteine 200 mg (STADA Vietnam, product declaration No. VD-22667-15) is an oral expectorant, which is prescribed as routine treatment for children and adults, respectively.
Study NCT05804123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xylometazoline Nasal
Description: Otrivin (Xylometazoline 0.05%) (Novartis VietNam, product declaration No. VN-15558-12) is a nasal-spraying decongestant, which is prescribed as routine treatment for children and adults, respectively.
Study NCT05804123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylometazoline Nasal
Description: Otrivin (Xylometazoline 0.05%) (Novartis VietNam, product declaration No. VN-15558-12) is a nasal-spraying decongestant, which is prescribed as routine treatment for children and adults, respectively.
Study NCT05804123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cefotaxime
Description: Imetoxim 1g (Cefotaxime 1g) (Imexpharm Pharmaceutical, product declaration No. VD-26846-17) is an injection or infusion-administrative antibiotic, which is prescribed as routine treatment for children.
Study NCT05804123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Description: Imetoxim 1g (Cefotaxime 1g) (Imexpharm Pharmaceutical, product declaration No. VD-26846-17) is an injection or infusion-administrative antibiotic, which is prescribed as routine treatment for children.
Study NCT05804123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciprofloxacin
Description: Ciprofloxacin 0.3% (Vidipha Central Pharmaceutical, product declaration No. VD-15205-11) is an antibiotic ear drop, which is prescribed as routine treatment for children.
Study NCT06309563 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aminoacid supplementation
Description: Low-calorie and low-protein diet + with 4 sachets of EEA-AC supplement per day for 2 weeks
Study NCT06309563 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Low-calorie and low-protein diet + placebo for 2 weeks
Study NCT05274958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-rated outcome measures and educational videos
Description: PROMs are scales that are validated in behavioral health for tracking symptoms of depression, anxiety, and other conditions. They can be self-administered or given by a clinician. Mytonomy videos are short, educational videos about the patient's primary condition. All patients receive PROMs on entering our clinic. The difference in this intervention is those randomized to the active treatment will receive monthly PROMs and mytonomy video(s) until their appointment with the clinician. Usual care patients will only have PROMs at the intake and then at the appointment with their assigned clinician.
Study NCT06172179 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: All procedures are observation. No intervention in this study.
Study NCT05804123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Ciprofloxacin 0.3% (Vidipha Central Pharmaceutical, product declaration No. VD-15205-11) is an antibiotic ear drop, which is prescribed as routine treatment for children.
Study NCT06466967 — intervention group
Intervention type: DEVICE
Intervention: Advanced hybrid closed-loop CamAPS FX
Description: Treatment with a strict programmed glucose target (80-99 mg/dL).
Study NCT04913311 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood, saliva, stool, and bronchoalveolar lavage samples
Study NCT04889508 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Socio-emotional mental training
Description: Core practice: Affect Dyad. In the Affect Dyad (AD), participants perform a 12-minute partner-based exercise which involves contemplating over one difficult situation and one situation which incurred gratitude in the past 24 hours. Both partners take turns speaking about the two situations while the other partner listens in a non-judgmental manner. While the participants elaborate on the situations, they are asked to focus on the bodily experience of the emotions generated during the situation. The goal of the exercise is to enhance coping with difficult emotions, empathic listening, social sharing, acceptance, and gratitude.
Study NCT04889508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Socio-emotional mental training
Description: Core practice: Affect Dyad. In the Affect Dyad (AD), participants perform a 12-minute partner-based exercise which involves contemplating over one difficult situation and one situation which incurred gratitude in the past 24 hours. Both partners take turns speaking about the two situations while the other partner listens in a non-judgmental manner. While the participants elaborate on the situations, they are asked to focus on the bodily experience of the emotions generated during the situation. The goal of the exercise is to enhance coping with difficult emotions, empathic listening, social sharing, acceptance, and gratitude.
Study NCT04889508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based mental training
Description: Core practice: Breathing Meditation. In this intervention, participants will practice 12-minute basic attention-based mindfulness meditation such as the Breathing Meditation (BM). BM is a 12-minute individual exercise that requires participants to focus their attention on the sensations of breathing. Participants have to sustain their attention to breath for long stretches of time, and have to return their attention to their breath when their mind wanders. The key focus is on training attention and interoceptive body awareness. Other practices participants will be taught is mindfulness on sounds (here the object of attention is not the breath but sounds in the environment).
Study NCT04913311 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy with Bronchoalveolar Lavage
Description: Undergo bronchoscopy with BAL
Study NCT05630950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smoking cessation mobile application
Description: Mobile application for smoking cessation.
Study NCT05630950 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written material for smoking cessation
Description: Written material for smoking cessation
Study NCT04913311 — intervention group
Intervention type: OTHER
Intervention: Chemoradiotherapy
Description: Undergo concurrent chemoradiation per standard of care
Study NCT04913311 — intervention group
Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo computed tomography scan
Study NCT05553925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Weight Management Program with Coaching and Patient Navigator Support
Description: Patients will enroll in a 12-month digital health program available in online and mobile versions with live, personalized coaching and patient navigator support.~Patient Interface~* Digital scale and Fitbit~* Brief lessons that focus on helping patients improve their nutrition, exercise, sleep, and stress~* Weight, diet, and physical activity tracking~* Regular, personalized feedback and support from a health coach~* Spanish Version~Patient navigators are non-licensed staff. Their responsibilities will include enrolling patients in the program, monitoring their progress, and updating providers periodically. They also will be able to connect patients with additional resources and services, such as the Center for Weight Management and Wellness, if appropriate.
Study NCT04913311 — intervention group
Intervention type: OTHER
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04913311 — intervention group
Intervention type: DRUG
Intervention: Immune Checkpoint Inhibitor
Description: Receive CPI per standard of care
Study NCT04913311 — intervention group
Intervention type: PROCEDURE
Intervention: Nasal Wash and Collection
Description: Undergo nasal wash
Study NCT04913311 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04913311 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04913311 — intervention group
Intervention type: PROCEDURE
Intervention: Spirometry
Description: Under lung spirometry tests
Study NCT06701149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rademikibart injection
Description: 300 mg administered subcutaneously on the first day
Study NCT06701149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBP-201 injection
Description: 300 mg administered subcutaneously on the first day
Study NCT06695988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating
Description: The intervention group will eat and drink in a prescribed daily feeding window of 8-hour between 6 a.m. to 8 p.m. for 8 weeks and follow their normal exercise and resistance training routines. We will allow +/-1 hour starting and ending times for the eating window while aiming for an 8-hour eating window
Study NCT06720064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Dressing
Description: Transparent catheter cover with Chlorhexidine (3M™ CHG Tegaderm™)
Study NCT06720883 — intervention group
Intervention type: PROCEDURE
Intervention: Major hepatectomy
Description: All patients will undergo robotic major hepatectomy with S1 resection, hilar lymphadenectomy and biliary reconstruction
Study NCT06719752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo intervention; the therapy will mimic exceptional mobilization.
Study NCT05338034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPG1860
Description: The dosage form for clinical research is a dry-filled capsule for oral administration manufactured as strengths of 3 mg, 5 mg, and 8 mg.
Study NCT05338034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study NCT04814121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suxiao Jiuxin Pills
Description: Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).
Study NCT04814121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The placebo of Suxiao Jiuxin Pills
Description: The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
Study NCT06566027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skeletal, dental, soft tissue index changes in Activator group
Description: After being interviewed and provided by a doctor with two kinds of appliances (Activator and EF class II standard) for treating class II malocclusion, the patients choose their appliance. The patients were separated into two groups (30 in each). Group 1 was treated with an Activator appliance (Activator group), whereas Group 2 was treated with an EF class II standard appliance (EF line group)
Study NCT06236919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR cognitive training
Description: The VR cognitive training group will engage in a subset of six games designed to target specific cognitive functions one game will target cognitive flexibility, requiring participants to switch between different tasks and problem-solving strategies quickly. Another game will focus on planning, asking participants to make a series of decisions to achieve a particular goal. Additionally, the Enhance VR group will also engage in games that target reappraisal strategies, working memory, divided and sustained attention, impulsivity, and processing speed.
Study NCT06236919 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR nature exposure relaxation
Description: The control group will be immersed in ten different nature-based VR environments (e.g., forests, lakes, beaches, etc.), where they will tailor its content and perform relaxation exercises (deep breathing techniques).
Study NCT05501106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Improvement strategies
Description: Integrated improvement strategies include postpartum hemorrhage risk screening, hierarchical management and preparedness, postpartum hemorrhage rescue recording, and review of postpartum hemorrhage cases.~1. A checklist (named as Risk Assessment and Preparedness for Postpartum Hemorrhage (Traffic Light in Delivery Room)) will be used in each virginal delivery to help obstetric staff and teams identify risk factors after admission, before and during labor, and improve the adherence to all known best practices.~2. The Postpartum Hemorrhage Rescue Format will be asked to be used in each postpartum hemorrhage rescue to record the rescue process.~3. Each case of postpartum hemorrhage exceeding 1000 ml will be reviewed. We will convene a QI Panel and a Task Force to assist the hospitals in postpartum hemorrhage case review and quality improvement strategy development.
Study NCT05527665 — intervention group
Intervention type: PROCEDURE
Intervention: Midurethral sling surgery
Description: This treatment consists of the placement of a sub-urethral sling, usually made of polypropylene, in order to support the urethra during efforts and thus to avoid leaks linked to its hyper mobility. This is a frequent and rapid surgery, which is performed on an outpatient basis. The sling is placed under the patient's urethra with the help of an awl.
Study NCT05266417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS-GSH
Description: Intranasal INS-GSH Twice Daily
Study NCT05266417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebos
Description: Intranasal Matched Placebos Twice Daily
Study NCT06721975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thulio pulsed Thulium:YAG (p-Tm:YAG)
Description: A new laser system developed by Dornier, the Thulio pulsed Thulium:YAG (p-Tm:YAG ) is beginning to be studied in vitro and in vivo. Dornier Thulio p-Tm:YAG may represent an attractive new laser platform, with comparable properties to TFL including decreased retropulsion, smaller dust, and improved ablation efficiency relative to Ho:YAG.